Natalia Sadetsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalia Sadetsky has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Gregory J. Riely
13 shared publicationsHuong Trinh
13 shared publicationsMichael T. Bretscher
13 shared publicationsMichael W. Lu
13 shared publicationsNavdeep Pal
13 shared publicationsNayan Chaudhary
13 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing the definitions used for each US geographic region
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing the definitions used for each US geographic region
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A schematic diagram of patient disposition and exclusion criteria
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A schematic diagram of patient disposition and exclusion criteria
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background:Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors.Methods:A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods.Results:The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.Conclusions:We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.Impact:These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background:Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors.Methods:A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods.Results:The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.Conclusions:We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.Impact:These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing baseline demographics and disease characteristics divided by SES index
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing baseline demographics and disease characteristics divided by SES index
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Additional detail on the methodology for subgroup analyses and statistical analyses
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Additional detail on the methodology for subgroup analyses and statistical analyses
- Open Access
- 29 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 588-596
Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- 29 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 588-596
Open AccessSociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Supplementary Figure from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Supplementary Figure from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Purpose:The utility of real-world data (RWD) for use as external controls in drug development is informed by studies that replicate trial control arms for different endpoints. The purpose of this study was to replicate control arms from four non–small cell lung cancer (NSCLC) randomized controlled trials (RCT) to analyze overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) using RWD.Patients and Methods:This study used RWD from a nationwide de-identified database and a clinico-genomic database to replicate OS, PFS, and ORR endpoints in the chemotherapy control arms of four first-line NSCLC RCTs evaluating atezolizumab [IMpower150–wild-type (WT), IMpower130-WT, IMpower131, and IMpower132]. Additional objectives were to develop a definition of real-world PFS (rwPFS) and to evaluate the real-world response rate (rwRR) endpoint.Results:Baseline demographic and clinical characteristics were balanced after application of propensity score weighting methods. For rwPFS and OS, RWD external controls were generally similar to their RCT control counterparts. Across all four trials, the hazard ratio (HR) point estimates comparing trial controls with external controls were closer to 1.0 for the PFS endpoint than for the OS endpoint. An exploratory assessment of rwRR in RWD revealed a slight but nonsignificant overestimation of RCT ORR, which was unconfounded by baseline characteristics.Conclusions:RWD can be used to reasonably replicate the OS and PFS of chemotherapy control arms of first-line NSCLC RCTs. Additional studies can provide greater insight into the utility of RWD in drug development.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Purpose:The utility of real-world data (RWD) for use as external controls in drug development is informed by studies that replicate trial control arms for different endpoints. The purpose of this study was to replicate control arms from four non–small cell lung cancer (NSCLC) randomized controlled trials (RCT) to analyze overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) using RWD.Patients and Methods:This study used RWD from a nationwide de-identified database and a clinico-genomic database to replicate OS, PFS, and ORR endpoints in the chemotherapy control arms of four first-line NSCLC RCTs evaluating atezolizumab [IMpower150–wild-type (WT), IMpower130-WT, IMpower131, and IMpower132]. Additional objectives were to develop a definition of real-world PFS (rwPFS) and to evaluate the real-world response rate (rwRR) endpoint.Results:Baseline demographic and clinical characteristics were balanced after application of propensity score weighting methods. For rwPFS and OS, RWD external controls were generally similar to their RCT control counterparts. Across all four trials, the hazard ratio (HR) point estimates comparing trial controls with external controls were closer to 1.0 for the PFS endpoint than for the OS endpoint. An exploratory assessment of rwRR in RWD revealed a slight but nonsignificant overestimation of RCT ORR, which was unconfounded by baseline characteristics.Conclusions:RWD can be used to reasonably replicate the OS and PFS of chemotherapy control arms of first-line NSCLC RCTs. Additional studies can provide greater insight into the utility of RWD in drug development.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Supplementary Table from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Supplementary Table from Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data